|
|
Volumn 13, Issue 10, 2007, Pages 1124-
|
|
Poor trial design leaves gene therapy death a mystery
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
TUMOR NECROSIS FACTOR ALPHA;
CLINICAL PRACTICE;
DEATH;
DRUG SAFETY;
GENE TARGETING;
GENE THERAPY;
HISTOPLASMOSIS;
HUMAN;
IMMUNE DEFICIENCY;
IMMUNOSUPPRESSIVE TREATMENT;
INTENSIVE CARE;
KIDNEY HEMORRHAGE;
METHODOLOGY;
NOTE;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
SYSTEMIC THERAPY;
ADULT;
ANTIBODIES, MONOCLONAL;
ANTIRHEUMATIC AGENTS;
CLINICAL TRIALS AS TOPIC;
FEMALE;
GENE THERAPY;
HISTOPLASMOSIS;
HUMANS;
MULTIPLE ORGAN FAILURE;
RESEARCH DESIGN;
|
|
EID: 34948868846
PISSN: 10788956
EISSN: 1546170X
Source Type: Journal
DOI: 10.1038/nm1007-1124a Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|
